Viatris, US92556V1061

Viatris stock: Pacira deal closes with 2026 revenue outlook

Published on 11/22/2026 at 13:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Viatris stock enters a new post-deal phase after Pacira became a wholly owned subsidiary. The transaction expands the drugmaker's non-opioid pain portfolio.

Pacira Adds A New Growth Platform

  • Viatris completed the Pacira acquisition on November 17, 2026, making Pacira a wholly owned subsidiary.
  • The transaction expands Viatris' position in non-opioid pain management and supports its U.S. innovative-medicines strategy.
  • Management expects Pacira to contribute 90 million to 100 million US dollars in revenue through December 31, 2026.
Viatris, US92556V1061, Illustration mit AI erstellt.

Viatris completed its acquisition of Pacira BioSciences on November 17, 2026, adding the non-opioid pain-management company as a wholly owned subsidiary. The company announced the closing in a Viatris release issued from Pittsburgh.

Deal Expands Innovative Medicines Portfolio

Viatris said its wholly owned subsidiary Peach Purchaser Sub accepted the shares tendered in the offer after all conditions were satisfied or waived. The subsidiary then merged with Pacira without a stockholder vote, leaving Pacira as the surviving wholly owned subsidiary of Viatris.

The tender offer expired on November 16, 2026. Pacira shareholders received 36.50 US dollars in cash per share, and Viatris said the aggregate amount payable in the offer and merger was approximately 1.69 billion US dollars, excluding related fees and expenses.

Pacira develops non-opioid pain treatments. Viatris CEO Scott A. Smith described the combination as part of the company's strategy to strengthen its U.S. innovative-medicines business and build a stronger position in non-opioid pain management.

Revenue Contribution Starts In 2026

Viatris expects the acquisition to contribute total revenue of between 90 million and 100 million US dollars from November 17 through December 31, 2026. The estimate covers the remaining period after the transaction closed and does not represent a full-year contribution.

Pacira's shares are set to be delisted from the Nasdaq Global Select Market following completion of the merger. Viatris remains listed on Nasdaq under the ticker VTRS.

Viatris Company Facts

  • Company: Viatris Inc.
  • ISIN: US92556V1061
  • Home exchange: Nasdaq
  • Ticker: VTRS
  • Acquired company: Pacira BioSciences

The Euro Stoxx 50 provides broader context for European equity markets.

More news and analyses on Viatris stock

Disclaimer...
en | US92556V1061 | VIATRIS | boerse | 70544394 | bgmi